These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27403743)

  • 1. Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.
    Hartmann A; Müllner J; Meier N; Hesekamp H; van Meerbeeck P; Habert MO; Kas A; Tanguy ML; Mazmanian M; Oya H; Abuaf N; Gaouar H; Salhi S; Charbonnier-Beaupel F; Fievet MH; Galanaud D; Arguillere S; Roze E; Degos B; Grabli D; Lacomblez L; Hubsch C; Vidailhet M; Bonnet AM; Corvol JC; Schüpbach M
    PLoS One; 2016; 11(7):e0158235. PubMed ID: 27403743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease.
    Cho SY; Shim SR; Rhee HY; Park HJ; Jung WS; Moon SK; Park JM; Ko CN; Cho KH; Park SU
    Parkinsonism Relat Disord; 2012 Sep; 18(8):948-52. PubMed ID: 22632852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy.
    Ruiz B; Serrano P; Moreno C
    J Investig Allergol Clin Immunol; 2016; 26(6):355-361. PubMed ID: 27996941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Combined Treatment with Acupuncture and Bee Venom Acupuncture as an Adjunctive Treatment for Parkinson's Disease.
    Cho SY; Lee YE; Doo KH; Lee JH; Jung WS; Moon SK; Park JM; Ko CN; Kim H; Rhee HY; Park HJ; Park SU
    J Altern Complement Med; 2018 Jan; 24(1):25-32. PubMed ID: 28753030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
    Maurice N; Deltheil T; Melon C; Degos B; Mourre C; Amalric M; Kerkerian-Le Goff L
    PLoS One; 2015; 10(11):e0142838. PubMed ID: 26571268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy.
    Eberlein-König B; Schmidt-Leidescher C; Rakoski J; Behrendt H; Ring J
    J Investig Allergol Clin Immunol; 2006; 16(1):5-10. PubMed ID: 16599242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Open-Label Study of Combined Treatment for Idiopathic Parkinson's Disease Using Acupuncture and Bee Venom Acupuncture as an Adjunctive Treatment.
    Doo KH; Lee JH; Cho SY; Jung WS; Moon SK; Park JM; Ko CN; Kim H; Park HJ; Park SU
    J Altern Complement Med; 2015 Oct; 21(10):598-603. PubMed ID: 26230989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibody response pattern (specific IgE and IgG) of insect sting allergic patients in immunotherapy with venom preparations].
    Wüthrich B; Arrendal H; Lanner A
    Schweiz Med Wochenschr; 1981 Nov; 111(46):1756-65. PubMed ID: 7313646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immunological response in patients with venom allergy during specific immunotherapy.
    Szymański W; Chyrek-Borowska S
    Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease.
    Zhao S; Cheng R; Zheng J; Li Q; Wang J; Fan W; Zhang L; Zhang Y; Li H; Liu S
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1214-8. PubMed ID: 26342560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals.
    Goldberg A; Confino-Cohen R
    Ann Allergy Asthma Immunol; 2007 Oct; 99(4):352-7. PubMed ID: 17941283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5.
    Müller UR; Johansen N; Petersen AB; Fromberg-Nielsen J; Haeberli G
    Allergy; 2009 Apr; 64(4):543-8. PubMed ID: 19120073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.